Study of ADCE-D01 for soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ADCE-D01 for people with soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have soft tissue sarcoma that has spread or cannot be surgically removed.
- You must have received at least 1 but no more than 2 types of chemotherapy for metastatic disease.
- Your cancer must be measurable on scans.
- You must be able to care for yourself (ECOG score 0 or 1).
- You must have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
This trial tests a new drug called HS-20093 combined with other treatments for people with advanced bone or soft tissue sarcoma. It aims to find safe and effective combinations for those who haven't responded to standard treatments.
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
This trial tests two injectable medications (OVV-01 and AK112) combined together to treat advanced soft tissue sarcoma—a cancer that has spread or cannot be surgically removed—in patients whose previous treatments have failed. The goal is to see if injecting these drugs directly into tumors can help shrink them and improve outcomes.
Hear when a new Metastatic Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.